Literature DB >> 1330564

Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin.

G Molinari1, P Paglia, G C Schito.   

Abstract

Exposure to subinhibitory concentrations (4-8 micrograms/ml) of azithromycin resulted in loss of motility in Proteus mirabilis strains and a significant reduction of motility in Pseudomonas aeruginosa strains. Examination revealed that the loss of motility was due to a total absence of flagella in Proteus mirabilis while the poor motility observed in Pseudomonas aeruginosa was due to absence of flagella in the majority of the population. Since motility may be considered a pathogenicity trait in the two species, these results confirm the unusual ability of azithromycin to reduce the expression of virulence factors in gram-negative pathogens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330564     DOI: 10.1007/bf01961867

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Immobilizing antibodies in urine. II. Prevention of ascending spread of Proteus mirabilis.

Authors:  G J Pazin; A I Braude
Journal:  Invest Urol       Date:  1974-09

2.  Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum.

Authors:  D Drake; T C Montie
Journal:  Can J Microbiol       Date:  1987-09       Impact factor: 2.419

3.  Practical procedure for demonstrating bacterial flagella.

Authors:  H Kodaka; A Y Armfield; G L Lombard; V R Dowell
Journal:  J Clin Microbiol       Date:  1982-11       Impact factor: 5.948

4.  Motility and chemotaxis of three strains of Pseudomonas aeruginosa used for virulence studies.

Authors:  R C Craven; T C Montie
Journal:  Can J Microbiol       Date:  1981-04       Impact factor: 2.419

5.  Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model.

Authors:  T C Montie; D Doyle-Huntzinger; R C Craven; I A Holder
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

6.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Comparative in vitro activity of the new oral macrolide azithromycin.

Authors:  H C Neu; N X Chin; G Saha; P Labthavikul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

8.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.

Authors:  I A Holder; R Wheeler; T C Montie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

Review 9.  The virulence of Pseudomonas aeruginosa.

Authors:  M Pollack
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

10.  Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa.

Authors:  H Ochi; H Ohtsuka; S Yokota; I Uezumi; M Terashima; K Irie; H Noguchi
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

View more
  17 in total

1.  Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis.

Authors:  K Kawamura-Sato; Y Iinuma; T Hasegawa; T Horii; T Yamashino; M Ohta
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.

Authors:  K Tateda; Y Ishii; T Matsumoto; N Furuya; M Nagashima; T Matsunaga; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 3.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

4.  Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.

Authors:  Yusuf Nalca; Lothar Jänsch; Florian Bredenbruch; Robert Geffers; Jan Buer; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  PA5470 Counteracts Antimicrobial Effect of Azithromycin by Releasing Stalled Ribosome in Pseudomonas aeruginosa.

Authors:  Jing Shi; Yiwei Liu; Yueying Zhang; Yongxin Jin; Fang Bai; Zhihui Cheng; Shouguang Jin; Weihui Wu
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium.

Authors:  Hidenori Matsui; Masahiro Eguchi; Katsufumi Ohsumi; Akio Nakamura; Yasunori Isshiki; Kachiko Sekiya; Yuji Kikuchi; Tohru Nagamitsu; Rokuro Masuma; Toshiaki Sunazuka; Satoshi Omura
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model.

Authors:  D P Nicolau; M A Banevicius; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

8.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

9.  Influence on Enterobacter cloacae metabolism, cell-surface hydrophobicity and motility of suprainhibitory concentrations of carbapenems.

Authors:  V Majtán; L Majtánová
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

10.  The multifaceted roles of antibiotics and antibiotic resistance in nature.

Authors:  Saswati Sengupta; Madhab K Chattopadhyay; Hans-Peter Grossart
Journal:  Front Microbiol       Date:  2013-03-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.